Bifogade filer
PR EN Change Of CMO 230901
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Kancera AB (publ) announces that Dr. Markus Jerling has been appointed as new Chief Medical Officer, effective from September 1, 2023.
Kancera announces today that Dr. Markus Jerling has been appointed as new Chief Medical Officer (CMO). Dr. Jerling has a PhD in clinical pharmacology and more than twenty-five years of experience of international drug development and has held various management positions in both Swedish and US companies. In addition to his experience of drug development in all clinical phases, he has fifteen years of experience from academic research and as a practising physician. During the first half of 2023, Kancera has contracted Dr. Jerling as subject matter expert in the fields of drug safety and PK/PD in connection with the KANDOVA study. Dr. Jerling will initially assume a position as part time consultant.
“We are very happy about Markus Jerling joining Kancera as he will contribute with his deep expertise in drug safety and clinical pharmacology as well as extensive general expertise of drug development”, says Peter Selin, CEO of Kancera.
Dr. Hanjing Xie, Kancera’s former CMO on a part-time consulting basis, is leaving the company and assuming a new position as CMO at Amal Therapeutics, a subsidiary of Boehringer Ingelheim headquartered in Geneva, Switzerland.
Peter Selin continues: “I fully understand Hanjing Xie’s decision to accept this new exciting position within the Boehringer Ingelheim group at Amal Therapeutics. I wish her the best of luck and would like to express my appreciation of her contributions to the initiation of the KANDOVA study”.
About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases, that today are lacking effective treatments. Kancera’s main focus is to develop small molecule drug candidates based on the fractalkine axis. The fractalkine axis is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.
For further information:
Peter Selin
CEO, Kancera AB
Phone: +46 (0)8-5012 60 80
Visit Kancera’s web page: https://www.kancera.com/en